Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | T5727 | — |
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | KH2BD | — |
extra dose given to the same patient) for PRIORIX and HAVRIX; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 3-year-old female patient who received HAV (Havrix) (batch number T5727, expiry date 06-MAY-2026) for prophylaxis. Co-suspect products included MMR (Priorix) (batch number KH2BD, expiry date 01-JAN-2026) for prophylaxis. On 29-JAN-2025, the patient received Havrix and Priorix. On 29-JAN-2025, an unknown time after receiving Havrix and Priorix, the patient experienced extra dose administered (Verbatim: extra dose given to the same patient) for PRIORIX and HAVRIX). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 28-FEB-2025 The health care professional reported that a patient received extra dose for Priorix and Havrix, which led to extra dose administered.